Adalimumab (Humira®)

The drug Adalimumab (trade name Humira®) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor alpha (TNF-α). Adalimumab was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:kappa constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and it consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. Adalimumab binds specifically to (TNF-α) and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Adalimumab in order to potentially avoid some side effects with a reliable method might be beneficial. Enzyme immunoassay (ELISA) test kit for the determination of free Adalimumab (Humira®) in serum and plasma. The catcher is TNF-α and the detection antibody is a HRP-labeled mAb binding at the Fc part of the drug. Due to the assay design there is full cross reactivity with other TNF-α catchers. This kit is for research use only, not for use in diagnostic procedures.